BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,279.50
- Market cap
- ₹15,699 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 92.5×Sector 46.1×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
- Value
- ₹0.02 Cr
AstraZeneca Pharma India Management Change
AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India reported receiving an ESG rating of 64 from Crisil ESG Ratings. The assessment was independently prepared using publicly available information.
Other other announcement announcements
All →Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.
Man Infraconstruction Other Announcement
Man Infraconstruction filed a Reg 32 quarterly statement confirming no deviation in use of preferential-warrant proceeds. No deviation or variation arose for the quarter ended September 30, 2026.
Black Buck Other Announcement
BlackBuck's ICRA monitoring agency report for Q1 FY27 confirms IPO proceeds utilization remains in line with stated objects. No deviation was observed in the quarter.
Raama Finance Other Announcement
Raama Finance appointed M/s. Kumar Gaurav & Co. as statutory auditor for three months effective October 29, 2026. The routine appointment carries no financial impact.
Teja Engineering Industries Other Announcement
Teja Engineering Industries filed a non-applicability certificate for Reg 27(2) Corporate Governance for Q1 FY27. As an NSE Emerge-listed SME, the company is exempt from this periodic disclosure.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.